Veru (VERU) Long-Term Deferred Tax (2010 - 2024)
Veru (VERU) posted quarterly Long-Term Deferred Tax of $12.7 million for Q3 2024, down 3.21% year-over-year from $13.2 million in Q4 2023, and up 2.06% quarter-over-quarter from $12.5 million in Q2 2024.
Veru (VERU) Long-Term Deferred Tax (2010 - 2024) Analysis & Trends
Veru (VERU) has reported Long-Term Deferred Tax for 15 consecutive years, with $12.7 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Long-Term Deferred Tax fell 3.21% year-over-year to $12.7 million; the TTM figure through Sep 2024 stood at $12.7 million (down 3.21% YoY), while the FY2024 annual figure was $12.7 million, down 3.21% from the prior year.
- Long-Term Deferred Tax climbed to $12.7 million in Q3 2024 per VERU's latest filing, from $12.5 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $13.2 million in Q3 2023 and bottomed at $8.6 million in Q2 2020.
- Historically, Long-Term Deferred Tax has averaged $11.9 million across 5 years, with a median of $12.8 million in 2023.
- Annual changes were most pronounced in 2021 — Long-Term Deferred Tax surged 43.48% — and 2024, when it decreased 4.72%.
- Veru's Long-Term Deferred Tax stood at $9.4 million in 2020, then jumped by 37.14% to $12.9 million in 2021, then gained by 0.94% to $13.1 million in 2022, then slipped by 2.02% to $12.8 million in 2023, then fell by 0.41% to $12.7 million in 2024.
- Business Quant data shows VERU's Long-Term Deferred Tax at $12.7 million in Q3 2024, $12.5 million in Q2 2024, and $12.6 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 12.74 Mn |
| Jun 30, 2024 | 12.48 Mn |
| Mar 31, 2024 | 12.64 Mn |
| Dec 31, 2023 | 12.79 Mn |
| Sep 30, 2023 | 13.16 Mn |
| Jun 30, 2023 | 13.10 Mn |
| Mar 31, 2023 | 13.07 Mn |
| Dec 31, 2022 | 13.05 Mn |
| Sep 30, 2022 | 12.97 Mn |
| Jun 30, 2022 | 13.01 Mn |
| Mar 31, 2022 | 13.02 Mn |
| Dec 31, 2021 | 12.93 Mn |
| Sep 30, 2021 | 13.02 Mn |
| Jun 30, 2021 | 12.38 Mn |
| Mar 31, 2021 | 9.44 Mn |
| Dec 31, 2020 | 9.43 Mn |
| Sep 30, 2020 | 9.47 Mn |
| Jun 30, 2020 | 8.63 Mn |
| Mar 31, 2020 | 8.63 Mn |
| Dec 31, 2019 | 8.59 Mn |